Clinical Trial Update: A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed [Phase 1]

View source ↗

Summary

A Phase 1 trial to determine a safe dose of volasertib added to salvage chemotherapy in children with acute myeloid leukemia after frontline chemotherapy failed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Volasertib (Volasertib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: WITHDRAWN